Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06236373 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia

Study acronym: Survivorship
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 9, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Notable Primary completion date: Feb 2024 to Feb 2025
    • Study completion date: Oct 2024 to Oct 2025
    • Site details revised
    • Publications: details revised at 1 of 7 entries
    v2
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5,418 trials monitored
See 296 trials at risk
3,394 trials monitored
See 159 trials at risk
and 3 more diseases
This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment. The primary objective is to utilize the experiences of patients, caregivers, and stakeholders to enhance the aftercare provided to cancer survivors. By delving into patient perceptions regarding unmet needs in cancer aftercare, the study aims to identify areas for redesigning and improving services to minimize these needs and ultimately enhance patient outcomes. Importantly, the investigation incorporates insights from patients, their caregivers, and stakeholders. The research will employ qualitative methods, specifically focus groups and interviews, to gather comprehensive perspectives from individuals in the Ausl IRCCS Reggio Emilia district who have completed treatment for breast, prostate, colorectal, thyroid, and multiple myeloma cancers. Including patients with diverse cancer types is crucial for capturing a broad spectrum of experiences. During data collection, both focus group discussions and interviews will be recorded in audio format and transcribed verbatim. This meticulous approach ensures an accurate representation of participants' voices and experiences. The subsequent analysis will employ a combination of framework and thematic analysis to extract meaningful insights and synthesize the data effectively. The study's ultimate goal is to leverage the findings to optimize aftercare services for cancer survivors within the local context of Ausl IRCCS Reggio Emilia. By incorporating the perspectives of patients, caregivers, and stakeholders, the research aims to contribute valuable insights that can inform the redesign and improvement of aftercare services, ultimately benefitting cancer survivors in the region.
Trial Details
NCT Number NCT06236373
Lead Sponsor University of Modena and Reggio Emilia
Collaborators: Azienda USL - IRCCS di Reggio Emilia
Conditions
(from sponsor)
Cancer, Breast Cancer, Prostate Cancer, Thyroid Cancer, Colorectal Cancer, Lymphoma, Multiple Myeloma, Neoplasms
Related terms Breast Neoplasms, Colorectal Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Prostatic Neoplasms, Thyroid Diseases, Thyroid Neoplasms
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov